Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

Nistor M, Don M, Parekh M, Sarsoza F, Goodus M, Lopez GE, Kawas C, Leverenz J, Doran E, Lott IT, Hill M, Head E.

Neurobiol Aging. 2007 Oct;28(10):1493-506. Epub 2006 Aug 9.

2.

The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein.

Tansley GH, Burgess BL, Bryan MT, Su Y, Hirsch-Reinshagen V, Pearce J, Chan JY, Wilkinson A, Evans J, Naus KE, McIsaac S, Bromley K, Song W, Yang HC, Wang N, DeMattos RB, Wellington CL.

J Lipid Res. 2007 May;48(5):1022-34. Epub 2007 Feb 10.

3.

Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Mehta PD, Capone G, Jewell A, Freedland RL.

J Neurol Sci. 2007 Mar 15;254(1-2):22-7. Epub 2007 Feb 2.

PMID:
17275850
4.

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ.

Neurobiol Dis. 1996 Feb;3(1):16-32.

PMID:
9173910
6.

Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition.

Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, Nixon RA.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1630-5. doi: 10.1073/pnas.0908953107. Epub 2009 Dec 28.

7.
8.

Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides.

Zhang Q, Yang G, Li W, Fan Z, Sun A, Luo J, Ke ZJ.

Neurobiol Aging. 2011 Jan;32(1):42-53. doi: 10.1016/j.neurobiolaging.2009.01.005. Epub 2009 Feb 23.

PMID:
19233513
9.

Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G.

Neurobiol Dis. 2001 Feb;8(1):173-80. Erratum in: Neurobiol Dis 2001 Jun;8(3):540.

PMID:
11162251
10.

Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.

Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, Stoeckli M, Rueeger H, Neumann U, Staufenbiel M.

J Pharmacol Exp Ther. 2008 Nov;327(2):411-24. doi: 10.1124/jpet.108.140327. Epub 2008 Aug 7.

11.

Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.

Evin G, Zhu A, Holsinger RM, Masters CL, Li QX.

J Neurosci Res. 2003 Nov 1;74(3):386-92.

PMID:
14598315
12.

Relationship between proteolytically cleaved gelsolin and levels of amyloid-β protein in the brains of Down syndrome subjects.

Ji L, Chauhan V, Mehta P, Wegiel J, Mehta S, Chauhan A.

J Alzheimers Dis. 2010;22(2):609-17. doi: 10.3233/JAD-2010-101029.

PMID:
20847428
13.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
14.

Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.

Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ.

J Neurosci Res. 2011 Jun;89(6):822-32. doi: 10.1002/jnr.22618. Epub 2011 Mar 23.

PMID:
21433051
15.

A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor.

Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, Ziani-Cherif C, Onstead L, Sambamurti K.

J Biol Chem. 2001 Jan 5;276(1):481-7.

16.

Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA.

Neurobiol Aging. 2004 Nov-Dec;25(10):1263-72.

PMID:
15465622
17.

Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.

Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG, Ericsson M, Soscia SJ, Mocofanescu A, Folkerth RD, Robb RM, Kuszak JR, Clark JI, Tanzi RE, Hunter DG, Goldstein LE.

PLoS One. 2010 May 20;5(5):e10659. doi: 10.1371/journal.pone.0010659.

18.

Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.

Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P.

Nat Med. 1996 Jan;2(1):93-5.

PMID:
8564851
19.

Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro.

Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu P.

Neurosci Lett. 2009 Mar 13;452(2):90-5. doi: 10.1016/j.neulet.2009.01.013. Epub 2009 Jan 13.

PMID:
19154776
20.

Protein expression of BACE1, BACE2 and APP in Down syndrome brains.

Cheon MS, Dierssen M, Kim SH, Lubec G.

Amino Acids. 2008 Aug;35(2):339-43. Epub 2007 Dec 29.

PMID:
18163181
Items per page

Supplemental Content

Write to the Help Desk